Market Segmentation by States by therapeutic classes: Cardiology, Oncology, Orthopedics

Market Segmentation by States by therapeutic classes: Cardiology, Oncology, Orthopedics

India Single Specialty Hospitals and Clinics Industry Outlook to 2019 - Day Care Specialty Clinics to Impel Growth” presents a comprehensive analysis of the industry covering aspects including market size by revenue and market segmentation by single specialty hospitals and clinics covering therapeutic classes such as Cardiology, Oncology, Orthopedics, Maternity and Urology and dental, eyecare, IVF and kidney dialysis. State wise presence of hospitals in each category is also presented as a segment of the market. A detailed analysis on total number of hospitals in major therapeutic classes, average revenue per bed per day in a therapeutic class, cost of treatments has been provided in the report. The report also entails a detailed description on the recent trends and developments, private equity investments in the sector, growth drivers and challenges and competitive landscape of major players in key therapeutic classes with revenue. Future Prospects of the industry along with future projections have been discussed.

India has the largest number of patients paying out of pocket expenses for medical purposes. This phenomenon has led to the emergence of the ‘healthcare consumer’ who is treated like a consumer and not just as a patient. The high expectations of healthcare consumers and the rise of branded private hospital chains have led to a shift in the consumer attitude towards doctors and hospitals. The healthcare sector in India which witnessed an initial wave of private investments in tertiary multi specialty hospitals, over the last decade, has witnessed spurring investments in single specialty chains. Some major names in single specialty hospitals in the country include: Fortis Escorts Heart and Research Centre (New Delhi), Tata Memorial Cancer Hospital (Mumbai), Sankara Nethralaya (Chennai), Vasan Eye Care (Chennai), HOSMAT Hospital (Bengaluru) among others.

Single specialty hospitals and clinics market in India has shown double digit growth rates over the last few years. The market revenue has escalated from INR ~ million in FY’2010 to INR ~ million in FY’2014. The industry has recorded a CAGR of 12.6% over the years FY’2010-FY’2014. Low capital investment and investment friendly business models have led to a spur of investments made in this business in India in the recent years. The share of hospitals in single specialty chains in total market value in the country stood at ~% in FY’2014, demurring from ~% in FY’2010.

Cardiology accounts for the maximum share of ~% in single specialty hospital market in India in terms of revenue, as recorded in FY’2014. Players such as Fortis Escorts Hearth Institute, Frontier Lifeline Hospital, Narayana Hrudayalaya have been recording impressive turnovers in the recent times, thus driving the market for cardiology hospitals in India. Oncology is the second largest revenue contributor to the SSH market in India. Maternity segment, at 4th largest position, was valued at INR ~ million in FY’2014 and has grown from INR ~ million in FY’2010. The specialties’ share in the overall SSH market has risen from ~% in FY’2010 to ~% in FY’2014. Urology forms a niche segment of single specialty hospitals industry in India with a share of ~% as recorded in FY’2014, however, the urology single specialty hospitals industry in the country has been displaying double digit growth rates in the past few years. The eyecare single specialty centres industry in India too has showcased stupendous growth of 30.8% over the years FY’2010-FY’2014.

Major healthcare chains such as Fortis healthcare, Apollo Hospitals have invested greatly in setting up single specialty centres for dialysis, maternity centres, and dental care centres in the country in the recent years. Fortis and Apollo have also established maternity centres in the country under the brand names, Fortis La Femme and Apollo Cradle, respectively.

The rapidly evolving single specialty hospital and clinics industry in India will change the facade of the healthcare sector in the coming years. The emergence of single specialty chains across a gamut of sub specialties with business models thriving on the ability to craft a custom solution for a specific requirement, backed by specialized infrastructure and medical personnel’s focused on providing quality care to the consumer will continue to drive growth in the coming years.

Provectus to sponsor AAPI of Indian origin, plans to participate in conferences in Mumbai

Provectus to sponsor AAPI of Indian origin, plans to participate in conferences in Mumbai

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (Provectus), has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.

Peter Culpepper, COO and CFO of Provectus, said, “We are very pleased to be sponsoring AAPI in the coming year, and we believe the relationship will benefit both AAPI and our shareholders. One of the benefits to Provectus will be engaging the Indian market through trusted physicians for PV-10, our novel investigational cancer treatment. We expect this will not only assist us in gaining regulatory approval in India but also will support our patient recruitment efforts as we embark on our phase 3 clinical trial of PV-10 for the treatment of melanoma.”

He continued, “AAPI is the umbrella organization representing the interests of over 60,000 doctors of Indian origin in the USA, and there are over 25,000 medical residents and fellows currently in USA. This gives us tremendous reach in America as well as on the subcontinent. One in every seven American patients is seen by an Indian doctor, and this ratio is even higher in the smaller towns and underserved areas due to the larger proportion of Indian doctors in more remote locations. As a result, the Indian doctor also serves the most diverse group of patients in the USA including Caucasians, African Americans, Hispanics and other groups, which is important for clinical research and trials.”

Culpepper concluded, “We will hit the ground running with AAPI by attending their Global Healthcare Summit (GHS) in Mumbai, India, starting January 2, 2015. At this GHS, we expect around 800 delegates to attend. Between 150 and 200 will be from the USA, and some from the United Kingdom, Canada, Middle East and Australia. In addition, AAPI will have a live extension to its members in the USA who are unable to attend, as well a live telecast to an estimated 50,000 doctors around India. We will inform this huge group of doctors from around the globe about the progress we have made with  PV-10 to date, what we are planning in the anticipated phase 3 clinical trial, and what we have learned about PV-10 for indications other than melanoma.”

Dr Ravi Jahagirdar, MD, president of AAPI, said, “We are very happy to have Provectus as an official sponsor of AAPI and to enjoy their participation at our coming meetings in Mumbai and Orlando in 2015. The Indian diaspora offers a unique, global network of physicians who can increase the communication of medical developments like the clinical results shown thus far for PV-10. Moreover, we have close professional, educational and family ties to India itself, a nation of 1 billion. We believe this introduction of Provectus to the healthcare industry in India will be well received, since PV-10 has many features that make it well suited for local conditions.”

 Provectus has also expanded the membership of its Strategic Advisory Board with the addition of  Deanna Angello, director, Commercial Strategy and New Business Planning for the Global Established Pharma business at Pfizer Inc. In this role, she is focused on new business opportunities for the US region, notably in areas such as licensing of new assets, mergers and acquisitions, and strategic partnerships. She was promoted to this position from her role as Senior Manager, Marketing, Lyrica, a product approved for fibomyalgia, diabetic peripheral neuropathy and other pain-related conditions. 

Dr Craig Dees, Ph.D., CEO of Provectus, said, “We are delighted to have Deanna join our Strategic Advisory Board. She is a highly experienced, forward-thinking healthcare and pharmaceutical strategist, with commercial experience in marketing and business development  and we look forward to working with her in the coming months.” 

Angello stated, “I am very pleased to be joining the Provectus Strategic Advisory Board just as they are beginning their phase 3 clinical trial of Intralesional PV-10 for the treatment of melanoma. It is a very exciting time for the Company both scientifically and commercially, and I look forward to contributing to its success.”

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects.

Cancer deaths on the rise in Nagaland

Cancer deaths on the rise in Nagaland

Despite various awareness programmes on hazardous effects of use of tobacco and a ban on sale of its products in the vicinity of educational institutions, a recent report paints a grim picture of the status of cancer in Nagaland. Use of tobacco is responsible for 90 per cent of oral cancer cases in the State. As per data provided by Indian Council of Medical Research (ICMR), the estimated prevalence rate of cancer in Nagaland was 4264 in 2011, 4307 in 2012 and 4353 in 2013 while the mortality rate was 695 in 2011, 702 in 2012 and 709 in 2013. About 67.9 per cent men and 28.1 per cent women in the State consume tobacco as per government sources.

In statewise details, Maharashtra topped the list with 43943 cases of deaths in 2013 while Lakshadweep is the lowest with 27 cases in the same year.

As per the recent PIB report, the number of doctors working in government sector having training in oncology and number of government medical colleges in the country which have oncology wards is not maintained centrally.

While doctors with DM (Medical Oncology), M.Ch (Surgical Oncology) and MD (Radiation Oncology) treat cancer patients in higher level tertiary care hospitals, Cancer is also being treated in hospitals by other doctors such as general surgeons, gynecologists, ENT surgeons etc., depending on the type and site of cancer. In fact, cancer is being diagnosed and treated at various levels in the government health care system. The government of India had assisted 27 regional cancer centres which have oncology wards.

The Central government has recently approved a scheme for enhancing the tertiary care cancer facilities in the country. Under this scheme, the Centre will assist 20 state cancer institutes (SCIs) and 50 tertiary care cancer centres (TCCCs) in different parts of the country.

The Central government is supplementing the efforts of the state governments for providing healthcare facilities including for cancer. The treatment in government hospitals is either free or subsidized. Financial assistance to below poverty line (BPL) patients is provided under the Rashtriya Arogya Nidhi (RAN). The Health Minister’s Cancer Patient Fund within RAN has been set up in 2009 wherein 27 erstwhile regional cancer centres (RCCs) are provided with revolving funds to provide immediate financial assistance upto Rs 1 lakh to BPL cancer patients.

New report looks into India's single specialty hospitals and clinics industry outlook to 2019

New report looks into India's single specialty hospitals and clinics industry outlook to 2019

This new report presents a comprehensive analysis of the industry covering aspects including market size by revenue and market segmentation by single specialty hospitals and clinics covering therapeutic classes such as Cardiology, Oncology, Orthopedics, Maternity and Urology and dental, eyecare, IVF and kidney dialysis.

State wise presence of hospitals in each category is also presented as a segment of the market. A detailed analysis on total number of hospitals in major therapeutic classes, average revenue per bed per day in a therapeutic class, cost of treatments has been provided in the report. The report also entails a detailed description on the recent trends and developments, private equity investments in the sector, growth drivers and challenges and competitive landscape of major players in key therapeutic classes with revenue. Future Prospects of the industry along with future projections have been discussed.

India Single Specialty Hospitals and Clinics MarketIndia has the largest number of patients paying out of pocket expenses for medical purposes. This phenomenon has led to the emergence of the ‘healthcare consumer’ who is treated like a consumer and not just as a patient. The high expectations of healthcare consumers and the rise of branded private hospital chains have led to a shift in the consumer attitude towards doctors and hospitals. The healthcare sector in India which witnessed an initial wave of private investments in tertiary multi specialty hospitals, over the last decade, has witnessed spurring investments in single specialty chains. Some major names in single specialty hospitals in the country include: Fortis Escorts Heart and Research Centre (New Delhi), Tata Memorial Cancer Hospital (Mumbai), Sankara Nethralaya (Chennai), Vasan Eye Care (Chennai), HOSMAT Hospital (Bengaluru) among others.

Single specialty hospitals and clinics market in India has shown double digit growth rates over the last few years. The market revenue has escalated from INR ~ million in FY’2010 to INR ~ million in FY’2014. The industry has recorded a CAGR of 12.6% over the years FY’2010-FY’2014. Low capital investment and investment friendly business models have led to a spur of investments made in this business in India in the recent years. The share of hospitals in single specialty chains in total market value in the country stood at ~% in FY’2014, demurring from ~% in FY’2010.

Cardiology accounts for the maximum share of ~% in single specialty hospital market in India in terms of revenue, as recorded in FY’2014. Players such as Fortis Escorts Hearth Institute, Frontier Lifeline Hospital, Narayana Hrudayalaya have been recording impressive turnovers in the recent times, thus driving the market for cardiology hospitals in India. Oncology is the second largest revenue contributor to the SSH market in India. Maternity segment, at 4th largest position, was valued at INR ~ million in FY’2014 and has grown from INR ~ million in FY’2010. The specialties’ share in the overall SSH market has risen from ~% in FY’2010 to ~% in FY’2014. Urology forms a niche segment of single specialty hospitals industry in India with a share of ~% as recorded in FY’2014, however, the urology single specialty hospitals industry in the country has been displaying double digit growth rates in the past few years. The eyecare single specialty centres industry in India too has showcased stupendous growth of 30.8% over the years FY’2010-FY’2014.

Major healthcare chains such as Fortis healthcare, Apollo Hospitals have invested greatly in setting up single specialty centres for dialysis, maternity centres, and dental care centres in the country in the recent years. Fortis and Apollo have also established maternity centres in the country under the brand names, Fortis La Femme and Apollo Cradle, respectively.

The rapidly evolving single specialty hospital and clinics industry in India will change the facade of the healthcare sector in the coming years. The emergence of single specialty chains across a gamut of sub specialties with business models thriving on the ability to craft a custom solution for a specific requirement, backed by specialized infrastructure and medical personnel’s focused on providing quality care to the consumer will continue to drive growth in the coming years.

Torrent partners with Reliance Life to sell biosimilars in India

Torrent partners with Reliance Life to sell biosimilars in India

Ahmedabad-based Torrent Pharmaceuticals Ltd today announced that the company has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in the Indian market.

In an announcement made on Thursday, Torrent Pharmaceuticals informed that Rituximab, Adalimumab and Cetuximab will be developed by Reliance Life Sciences and supplied to Torrent Pharma after obtaining all necessary regulatory approvals. Torrent Pharma will be the only company to market these biosimilars in India other than Reliance Life Sciences, a company statement said here.

As per the terms of agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of ten years.

Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers like leukemia, lymphoma, colorectal, head and neck cancers. Adalimumab is the most preferred therapy for the treatment of auto immune disorders like rheumatoid arthritis, psoriasis and IBD.

"Torrent Pharma forayed into the oncology and dermatology segments in 2011-12 with the launch of exclusive divisions and has since gained a strong position in these segments. The licensing agreement with Reliance Life Sciences is expected to significantly boost its presence in these segments in the coming years," it said.

Myriad Genetics' Ovarian Cancer Test Wins FDA Approval

Myriad Genetics' Ovarian Cancer Test Wins FDA Approval

Utah-based molecular diagnostics provider Myriad Genetics, Inc. has received the FDA approval for its well acclaimed molecular companion diagnostic test – BracAnalysis CDx.

Myriad Genetics' BracAnalysis CDx has become the first and only FDA-approved test to be permitted for use with AstraZeneca's  latest FDA-cleared ovarian cancer drug – LynParza – for the treatment of women with advanced ovarian cancer.

Myriad's BracAnalysis CDx is a highly accurate molecular companion diagnostic test that can detect the presence of BRCA1 and BRCA2 gene mutations by examining a patient's blood sample. Evidently, through clinical studies, it has been observed that BracAnalysis CDx can effectively recognize patients with BRCA mutations, who can then be treated with Lynparza.

Women with mutations resulting in defective BRCA genes are more likely to contract ovarian cancer. It is estimated that 10–15% of all ovarian cancer cases is associated with hereditary BRCA mutations.

Management at Myriad believes this FDA approval will open up new roads for personalized treatment of ovarian cancer patients who can potentially be treated with a new class of drugs like Lynparza.

At the European Society of Medical Oncology meeting, data presented by Myriad showed that its tumor BracAnalysis CDx can identify approximately 44% more ovarian cancer patients who are likely to respond to olaparib than conventional germline BRAC testing. This has significantly enhanced the potential market for olaparib and the significance of the BracAnalysis CDx test.

However, less than 25% of ovarian cancer patients know their germline BRCA status, the knowledge of which is crucial for treatment with Lynparza. This implies that Myriad's BracAnalysis test has significant untapped opportunity to capitalize on, going ahead.

Currently, Myriad is engaged in active partnership with several biopharmaceutical companies to further evaluate BRACAnalysis CDx as an investigational companion diagnostic for use with other PARP inhibitors and chemotherapeutic agents and for use in many other solid tumor types.

Myriad expects to get a revenue benefit in the second half of fiscal 2015 from BracAnalysis CDx, once Lynparza gets the FDA nod. We believe the aforementioned FDA go-ahead serves as a stepping-stone for the same.

Novartis India Ltd reply to clarification sought by the exchange

Novartis India Ltd reply to clarification sought by the exchange

The Exchange had sought clarification from Novartis India Ltd with respect to news article appearing in The Economic Times on December 24, 2014 titled "CCI gives approval for Novartis-GSK Pharma Deal"

Novartis India Ltd replied stating "Novartis AG and GSK plc have agreed to create a consumer healthcare business through a global joint venture between the OTC division of Novartis and the consumer healthcare division of GSK. The global transaction is subject to various closing conditions including obtaining anti-trust approvals. Novartis India Limited had informed BSE Limited of this by its disclosure dated 22 May 2014.

Accordingly, both Novartis AG and GSK plc had sought the approval of the Competition Commission of India for the global consumer healthcare joint venture between Novartis and GSK along with approval for the divestment of Novartis Vaccines business to GSK and the acquisition by Novartis of GSKs Oncology business. Please note that only the OTC division is housed within Novartis India Limited. The Commission approved the transactions mentioned above by way of its order published on 23 December 2014.

The combination of the OTC division of Novartis with the consumer healthcare division of GSK has, however, not yet been considered by the board of directors of Novartis India Limited and the company is yet to enter into definitive agreements with GSK in this regard. Such agreements when entered into will be subject to all necessary regulatory approvals. Novartis India Limited will make appropriate disclosures to the stock exchange in accordance with the companys obligations under the listing agreement as and when its board considers the transaction."